The downgrade from Buy to Hold by a major financial institution like HSBC suggests a more cautious outlook on AbbVie's stock, which could lead to a negative short-term reaction in the market. The reduction in the price target further reinforces the expectation of a lower valuation, potentially influencing investor sentiment and stock price.